Endo International PLC’s (NASDAQ:ENDP) “Buy” Rating Reaffirmed at Mizuho

Endo International PLC (NASDAQ:ENDP)‘s stock had its “buy” rating reissued by Mizuho in a note issued to investors on Thursday. They presently have a $19.00 price objective on the stock. Mizuho’s target price indicates a potential upside of 139.29% from the company’s previous close.

Other analysts have also issued research reports about the company. Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the company a “hold” rating in a report on Monday, May 1st. Guggenheim began coverage on Endo International PLC in a report on Saturday, June 17th. They issued a “hold” rating and a $12.00 target price on the stock. Royal Bank Of Canada raised their target price on Endo International PLC from $9.00 to $15.00 and gave the company a “sector perform” rating in a report on Wednesday. Deutsche Bank AG set a $13.00 target price on Endo International PLC and gave the company a “buy” rating in a report on Wednesday. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a report on Thursday, June 8th. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $16.02.

Endo International PLC (NASDAQ:ENDP) opened at 7.94 on Thursday. The stock’s 50 day moving average price is $11.36 and its 200 day moving average price is $11.72. The stock’s market capitalization is $1.77 billion. Endo International PLC has a 1-year low of $7.81 and a 1-year high of $24.93.

Endo International PLC (NASDAQ:ENDP) last released its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 25.32% and a negative net margin of 82.93%. The company’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.86 EPS. Equities research analysts forecast that Endo International PLC will post $3.53 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Endo International PLC’s (NASDAQ:ENDP) “Buy” Rating Reaffirmed at Mizuho” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://sportsperspectives.com/2017/08/10/endo-international-plcs-nasdaqendp-buy-rating-reaffirmed-at-mizuho.html.

A number of hedge funds have recently made changes to their positions in the stock. Icon Advisers Inc. Co. increased its position in shares of Endo International PLC by 314.4% in the first quarter. Icon Advisers Inc. Co. now owns 74,600 shares of the company’s stock valued at $833,000 after buying an additional 56,600 shares during the last quarter. Comerica Bank increased its position in shares of Endo International PLC by 233.7% in the first quarter. Comerica Bank now owns 153,881 shares of the company’s stock valued at $1,736,000 after buying an additional 107,761 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the last quarter. Point View Wealth Management Inc. increased its position in shares of Endo International PLC by 12.3% in the first quarter. Point View Wealth Management Inc. now owns 11,431 shares of the company’s stock valued at $128,000 after buying an additional 1,254 shares during the last quarter. Finally, Capital Fund Management S.A. acquired a new position in shares of Endo International PLC during the first quarter valued at about $260,000. 93.00% of the stock is currently owned by institutional investors and hedge funds.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply